I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Core Viewpoint - I-Mab has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 for its American Depositary Shares (ADS) [1][2] Group 1: Compliance Status - The company has not met the minimum bid price requirement from February 3, 2025, to March 18, 2025, as per Nasdaq Listing Rule 5450(a)(1) [1] - I-Mab has until September 15, 2025, to regain compliance by maintaining a closing bid price of at least$1.00 per ADS for ten consecutive business days [2] - If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day period or face potential delisting [2][3] Group 2: Company Actions - The company is actively monitoring the closing bid price of its ADSs and evaluating options to regain compliance with Nasdaq's listing requirements [3] - I-Mab intends to use all reasonable efforts to achieve compliance with the minimum bid requirement [3][4] - The company has expressed its commitment to resolve the deficiency and regain compliance with the Listing Rules [4] Group 3: Company Overview - I-Mab is a US-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment [5]